Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Jing Wen, Xin Li, Qing-Xia Zhao, Xiao-Fan Yang, Meng-Li Wu, Qihong Yan, Junbiao Chang, Haikun Wang, Xia Jin, Xiao Su, Kai Deng, Ling Chen & Jian-Hua Wang. (2022) Pharmacological suppression of glycogen synthase kinase-3 reactivates HIV-1 from latency via activating Wnt/β-catenin/TCF1 axis in CD4+ T cells. Emerging Microbes & Infections 11:1, pages 392-406.
Read now
Read now
Carlos Roca & Nuria E. Campillo. (2020) Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2016–2019). Expert Opinion on Therapeutic Patents 30:11, pages 863-872.
Read now
Read now
Ilyas Sahin, Aditya Eturi, Andre De Souza, Sahithi Pamarthy, Fabio Tavora, Francis J. Giles & Benedito A. Carneiro. (2019) Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses. Cancer Biology & Therapy 20:8, pages 1047-1056.
Read now
Read now
Articles from other publishers (36)
Libo Hua, Farah Anjum, Alaa Shafie, Amal Adnan Ashour, Abdulraheem Ali Almalki, Ali Abdullah Alqarni, Hamsa Jameel Banjer, Sarah Abdullah Almaghrabi, Shan He & Nenggui Xu. (2023) Identifying promising GSK3β inhibitors for cancer management: a computational pipeline combining virtual screening and molecular dynamics simulations. Frontiers in Chemistry 11.
Crossref
Crossref
Andreas Gollner, Claudia Heine & Karin S. Hofbauer. (2023) Kinase Degraders, Activators, and Inhibitors: Highlights and Synthesis Routes to the Chemical Probes on opnMe.com, Part 1. ChemMedChem 18:10.
Crossref
Crossref
Debarati DasGupta, Ramin Mehrani, Heather A. Carlson & Sumit Sharma. (2023) Identifying Potential Ligand Binding Sites on Glycogen Synthase Kinase 3 Using Atomistic Cosolvent Simulations. ACS Applied Bio Materials.
Crossref
Crossref
Richard A. Hartz, Vijay T. Ahuja, Prasanna Sivaprakasam, Hong Xiao, Carol M. Krause, Wendy J. Clarke, Kevin Kish, Hal Lewis, Nicolas Szapiel, Ramu Ravirala, Sayali Mutalik, Deepa Nakmode, Devang Shah, Catherine R. Burton, John E. Macor & Gene M. Dubowchik. (2023)
Design, Structure–Activity Relationships, and In Vivo Evaluation of Potent and Brain-Penetrant Imidazo[1,2-
b
]pyridazines as Glycogen Synthase Kinase-3β (GSK-3β) Inhibitors
. Journal of Medicinal Chemistry 66:6, pages 4231-4252.
Crossref
Crossref
Su-ling Huang, Wei Xie, Yang-liang Ye, Jia Liu, Hui Qu, Yu Shen, Ti-fei Xu, Zhuo-hui Zhao, Yu Shi, Jian-hua Shen & Ying Leng. (2022) Coronarin A modulated hepatic glycogen synthesis and gluconeogenesis via inhibiting mTORC1/S6K1 signaling and ameliorated glucose homeostasis of diabetic mice. Acta Pharmacologica Sinica 44:3, pages 596-609.
Crossref
Crossref
Catherine Hottin, Muriel Perron & Jérôme E. Roger. (2022) GSK3 Is a Central Player in Retinal Degenerative Diseases but a Challenging Therapeutic Target. Cells 11:18, pages 2898.
Crossref
Crossref
Teresa Gianferrara, Eleonora Cescon, Ilenia Grieco, Giampiero Spalluto & Stephanie Federico. (2022) Glycogen Synthase Kinase 3β Involvement in Neuroinflammation and
Neurodegenerative Diseases. Current Medicinal Chemistry 29:27, pages 4631-4697.
Crossref
Crossref
Abhijit Das, Barshana Bhattacharya & Souvik Roy. (2022) Decrypting a path based approach for identifying the interplay between PI3K and GSK3 signaling cascade from the perspective of cancer. Genes & Diseases 9:4, pages 868-888.
Crossref
Crossref
Chirag Khurana & Onkar Bedi. (2022) Proposed hypothesis of GSK-3 β inhibition for stimulating Wnt/β-catenin signaling pathway which triggers liver regeneration process. Naunyn-Schmiedeberg's Archives of Pharmacology 395:3, pages 377-380.
Crossref
Crossref
Li Wang, Jiajia Li & Li‐jun Di. (2021) Glycogen synthesis and beyond, a comprehensive review of GSK3 as a key regulator of metabolic pathways and a therapeutic target for treating metabolic diseases. Medicinal Research Reviews 42:2, pages 946-982.
Crossref
Crossref
Sara Melisa Arciniegas Ruiz & Hagit Eldar-Finkelman. (2022) Glycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward. Frontiers in Molecular Neuroscience 14.
Crossref
Crossref
Stefania Demuro, Rita M. C. Di Martino, Jose A. Ortega & Andrea Cavalli. (2021) GSK-3β, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways. International Journal of Molecular Sciences 22:16, pages 9098.
Crossref
Crossref
Anabel Rico, Garazi Guembelzu, Valle Palomo, Ana Martínez, Ana Aiastui, Leire Casas-Fraile, Andrea Valls, Adolfo López de Munain & Amets Sáenz. (2021) Allosteric Modulation of GSK-3β as a New Therapeutic Approach in Limb Girdle Muscular Dystrophy R1 Calpain 3-Related. International Journal of Molecular Sciences 22:14, pages 7367.
Crossref
Crossref
Ning Zhang, Yu-Nan Tian, Li-Na Zhou, Meng-Zhu Li, Hua-Dong Chen, Shan-Shan Song, Xia-Juan Huan, Xu-Bin Bao, Ao Zhang, Ze-Hong Miao & Jin-Xue He. (2021) Glycogen synthase kinase 3β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer. Cell Death & Disease 12:2.
Crossref
Crossref
William D. Hedrich & Hongbing Wang. (2021) Friend or Foe: Xenobiotic Activation of Nrf2 in Disease Control and Cardioprotection. Pharmaceutical Research 38:2, pages 213-241.
Crossref
Crossref
Ido Rippin & Hagit Eldar-Finkelman. (2021) Mechanisms and Therapeutic Implications of GSK-3 in Treating Neurodegeneration. Cells 10:2, pages 262.
Crossref
Crossref
Shan-Kui Liu, Hong-Xu Xie, Yong-Xi Ge, Juan Zhang & Cheng-Shi Jiang. (2021) An updated research of glycogen synthase kinase-3β inhibitors: a review. Monatshefte für Chemie - Chemical Monthly 152:1, pages 19-33.
Crossref
Crossref
Tayebeh Noori, Ahmad Reza Dehpour, Antoni Sureda, Sajad Fakhri, Eduardo Sobarzo-Sanchez, Mohammad Hosein Farzaei, Esra Küpeli Akkol, Zahra Khodarahmi, Seyede Zahra Hosseini, Seyede Darya Alavi & Samira Shirooie. (2020) The role of glycogen synthase kinase 3 beta in multiple sclerosis. Biomedicine & Pharmacotherapy 132, pages 110874.
Crossref
Crossref
Marianne Comeau-Gauthier, Magdalena Tarchala, Jose Luis Ramirez-Garcia Luna, Edward Harvey & Geraldine Merle. (2020) Unleashing β-catenin with a new anti-Alzheimer drug for bone tissue regeneration. Injury 51:11, pages 2449-2459.
Crossref
Crossref
Takahiro Domoto, Masahiro Uehara, Dilireba Bolidong & Toshinari Minamoto. (2020) Glycogen Synthase Kinase 3β in Cancer Biology and Treatment. Cells 9:6, pages 1388.
Crossref
Crossref
Ahmad Abu Turab Naqvi, Gulam Mustafa Hasan & Md. Imtaiyaz Hassan. (2020) Targeting Tau Hyperphosphorylation via Kinase Inhibition: Strategy to Address Alzheimer's Disease. Current Topics in Medicinal Chemistry 20:12, pages 1059-1073.
Crossref
Crossref
Runxuan Lin, Nigel Charles Jones & Patrick Kwan. (2020) Unravelling the Role of Glycogen Synthase Kinase-3 in Alzheimer’s Disease-Related Epileptic Seizures. International Journal of Molecular Sciences 21:10, pages 3676.
Crossref
Crossref
Camilla Evangelisti, Francesca Chiarini, Francesca Paganelli, Sandra Marmiroli & Alberto M. Martelli. (2020) Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1867:4, pages 118635.
Crossref
Crossref
Yongxin Han, Li Zhu, Wei Wu, Hui Zhang, Wei Hu, Liguang Dai & Yanqing Yang. 2020. Regulation of Cancer Immune Checkpoints. Regulation of Cancer Immune Checkpoints
547
618
.
Diego Lastra, Raquel Fernández-Ginés, Gina Manda & Antonio Cuadrado. 2021. Reactive Oxygen Species. Reactive Oxygen Species
93
141
.
Guilherme Martins Silva, Mariana Pegrucci Barcelos, João Gabriel Curtolo Poiani, Lorane Izabel da Silva Hage‐Melim & Carlos Henrique Tomich de Paula da Silva. (2019) Allosteric Modulators of Potential Targets Related to Alzheimer's Disease: a Review. ChemMedChem 14:16, pages 1467-1483.
Crossref
Crossref
Natalia Robledinos-Antón, Raquel Fernández-Ginés, Gina Manda & Antonio Cuadrado. (2019) Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development. Oxidative Medicine and Cellular Longevity 2019, pages 1-20.
Crossref
Crossref
Siddavaram Nagini, Josephraj Sophia & Rajakishore Mishra. (2019) Glycogen synthase kinases: Moonlighting proteins with theranostic potential in cancer. Seminars in Cancer Biology 56, pages 25-36.
Crossref
Crossref
M. Xu, S.L. Wang, L. Zhu, P.Y. Wu, W.B. Dai & K.P. Rakesh. (2019) Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3β inhibitors: A critical review. European Journal of Medicinal Chemistry 164, pages 448-470.
Crossref
Crossref
Alonso Sánchez-Cruz, Ana Martínez, Enrique J. de la Rosa & Catalina Hernández-Sánchez. 2019. Retinal Degenerative Diseases. Retinal Degenerative Diseases
437
441
.
Annachiara Gandini, Manuela Bartolini, Daniele Tedesco, Loreto Martinez-Gonzalez, Carlos Roca, Nuria E. Campillo, Josefa Zaldivar-Diez, Concepción Perez, Giampaolo Zuccheri, Andrea Miti, Alessandra Feoli, Sabrina Castellano, Sabrina Petralla, Barbara Monti, Martina Rossi, Fabio Moda, Giuseppe Legname, Ana Martinez & Maria Laura Bolognesi. (2018) Tau-Centric Multitarget Approach for Alzheimer’s Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors. Journal of Medicinal Chemistry 61:17, pages 7640-7656.
Crossref
Crossref
Antonio Cuadrado, Gina Manda, Ahmed Hassan, María José Alcaraz, Coral Barbas, Andreas Daiber, Pietro Ghezzi, Rafael León, Manuela G. López, Baldo Oliva, Marta Pajares, Ana I. Rojo, Natalia Robledinos-Antón, Angela M. Valverde, Emre Guney & Harald H. H. W. Schmidt. (2018) Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach. Pharmacological Reviews 70:2, pages 348-383.
Crossref
Crossref
Tina M Thornton, Brendan Hare, Sandra Colié, William W Pendlebury, Angel R Nebreda, William Falls, Diane M Jaworski & Mercedes Rincon. (2017) Failure to Inactivate Nuclear GSK3β by Ser389-Phosphorylation Leads to Focal Neuronal Death and Prolonged Fear Response. Neuropsychopharmacology 43:2, pages 393-405.
Crossref
Crossref
A. Prasanth Saraswati, S.M. Ali Hussaini, Namballa Hari Krishna, Bathini Nagendra Babu & Ahmed Kamal. (2018) Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions. European Journal of Medicinal Chemistry 144, pages 843-858.
Crossref
Crossref
Valle Palomo, Daniel I. Perez, Carlos Roca, Cara Anderson, Natalia Rodríguez-Muela, Concepción Perez, Jose A. Morales-Garcia, Julio A. Reyes, Nuria E. Campillo, Ana M. Perez-Castillo, Lee L. Rubin, Lubov Timchenko, Carmen Gil & Ana Martinez. (2017) Subtly Modulating Glycogen Synthase Kinase 3 β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases. Journal of Medicinal Chemistry 60:12, pages 4983-5001.
Crossref
Crossref
Li Wang, Jiagao Cheng, Shuai Wang, Xichen Zhang & Xuepeng Cai,. (2017) Screening of inhibitors of Taenia solium glycogen synthase Kinase-3β. RSC Advances 7:68, pages 43319-43326.
Crossref
Crossref